<DOC>
	<DOCNO>NCT00047242</DOCNO>
	<brief_summary>RATIONALE : UCN-01 may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining UCN-01 chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine UCN-01 irinotecan treating patient advance solid tumor .</brief_summary>
	<brief_title>UCN-01 Irinotecan Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose UCN-01 irinotecan patient advance solid tumor , primarily lung , ovarian , gastrointestinal tumor . - Determine acute chronic toxicity profile regimen patient . - Determine pharmacokinetics regimen patient . - Determine , preliminarily , anti-tumor effect regimen patient . OUTLINE : This dose-escalation study . Patients receive UCN-01 IV 3 hour day 1 irinotecan IV 90 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos UCN-01 irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treat recommended phase II dose . Patients follow 1 month . PROJECTED ACCRUAL : Approximately 20-30 patient accrue study within 7-15 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy metastatic unresectable standard curative palliative therapy exist longer effective Gastrointestinal , lung , ovarian malignancy give priority No brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin normal AST/ALT great 2.5 time upper limit normal ( ULN ) Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic coronary artery disease No symptomatic cardiac dysfunction No symptom suggestive coronary artery disease LVEF least 50 % Pulmonary No symptomatic pulmonary dysfunction FEV_1 great 75 % predict DLCO great 75 % predict Other Amylase great 2 time ULN No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No diabetes mellitus random glucose 200 mg/dL No prior allergic reaction attribute compound similar biological chemical composition UCN01 irinotecan ( include rash systemic allergic reaction cause hypotension respiratory distress ) No chronic diarrhea ( 5 stools/day ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 14 day , , least 30 day study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior UCN01 irinotecan allow Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy recover No prior mediastinal radiation Surgery Not specify Other At least 14 day since prior warfarin No concurrent warfarin unless require maintaining patency exist , permanent IV catheters No concurrent commercial investigational anticancer agent therapies No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>